MRI systems market will reach $9.27bn in 2020, according to new visiongain data.

31 August 2018
Pharma

A new report by visiongain, published in October 2016, forecasts that overall sales of magnetic resonance imaging (MRI) equipment will reach $9.27 billion worldwide in 2020. That revenue growth will continue strongly through to 2026, with rising demand for early and effective diagnostic procedures and advances in MRI technology.

That revenue prediction and others appear in Magnetic Resonance Imaging (MRI) Systems: Market Forecasts 2016-2026 – Report Assessing Medical Imaging Technologies Including High, Medium and Low-Field Equipment, Discussing Companies such as GE Healthcare, Toshiba, Siemens and Philips, with Revenue Predictions for Sales in the US, Japan, Germany, France, the UK, Italy, Spain, China, India, Brazil and Russia. Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations assess commercial prospects of industries and markets in healthcare and other fields.

Visiongain’s new study analyses events, progress and opportunities shaping the development, production and marketing of MRI products. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing MRI systems. The MRI devices market holds many commercial and technological opportunities from 2016, including rising sales in developed and emerging countries.

Revenue expansion for MRI products is driven by the rising incidence and prevalence of chronic diseases worldwide, which stimulates demand for improved medical diagnostic procedures in mature and rising national markets. Advances in MRI technology from 2016 to 2026 to improve efficacy and allow scans to be more accurate will benefit MRI companies and their industry, as well as healthcare providers and patients.

Aanchal Verma, a pharmaceutical and healthcare industry analyst in visiongain, said: “A key factor in the growth of the medical devices market is MRI systems, which has progressed rapidly in recent years owing primarily to an increased patient demand for early and effective diagnosis of diseases. Technological advances propelled the field of MRI, with new and innovative devices that scan regions of the body previously thought as difficult to image.

“The improving healthcare systems and economic prosperity in the emerging national markets will be a main driver of growth within the MRI devices market. Furthermore, the rise in incidence of chronic diseases, improvements in technology, awareness of early screening and the demand for improved diagnostics will fuel strong demand for MRI devices globally.”

Visiongain’s investigation shows forecasts at overall world market, submarket and national level. First that study gives individual revenue predictions to 2026 for four segments of the worldwide magnetic resonance imaging market:

• High-field equipment
• Medium-field systems
• Low-field devices
• Other related products.

The new report also breaks its overall world market forecast into individual revenue predictions to 2026 for these leading national markets:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

In addition the study assesses leading companies in that medical diagnostics and imaging field, including these organisations:

• GE Healthcare
• Toshiba
• Siemens
• Philips.

Magnetic Resonance Imaging (MRI) Systems: Market Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers medical devices, diagnostics, pharmaceuticals, biotechnologies and outsourced services. Each year new and updated studies appear there, helping readers explore markets’ developments and potentials.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever